Shares of Dr Reddy's Laboratories today plunged over 10 per cent following a decision made by the District Court of New Jersey with respect to further sale and commercialisation of its product in the US.
The stock slumped 9.85 per cent to end at Rs 2,089.15 on the BSE. Intra-day, it plummeted 10.61 per cent to Rs 2,071.50.
On the NSE, shares of the company tanked 10.20 per cent to close at Rs 2,083.
Led by the sharp fall in the stock, the company's market valuation dropped Rs 3,787.49 crore to Rs 34,661.51 crore.
In terms of equity volume, 3.24 lakh shares of the company were traded on the BSE and over 37 lakh shares changed hands on the NSE during the day.
Dr Reddy's Laboratories on Saturday said it will appeal the decision of the US District Court of New Jersey regarding further sale and commercialisation of its Buprenorphine and Naloxone sublingual film in America.
"The company disagrees with the court's decision, and will vigorously appeal it," Dr Reddy's said in a BSE filing.
The company intends to appeal the decision made by the US District Court of New Jersey in a preliminary injunction hearing with respect to further sale and commercialisation of its product in the US, it added.
The product is indicated for the treatment of opioid dependence.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app